Cancer vaccine MUC-1 - Immutep Limited

Drug Profile

Cancer vaccine MUC-1 - Immutep Limited

Alternative Names: CVac; M-FP cancer vaccine; Mannan-MUC1 fusion protein; MUC1 dendritic cell vaccine

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prima Biomed
  • Developer Prima BioMed
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 28 Nov 2017 Prima BioMed is now called Immutep Limited
  • 19 May 2015 Updated efficacy results from a phase II trial in Ovarian cancer released by Prima BioMed
  • 01 Apr 2015 Prima BioMed completes a phase II trial for Ovarian cancer in USA and Australia (NCT01068509)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top